CD30 靶点蛋白|抗体药物|临床药物信息

CD30信息

英文名称：Tumor necrosis factor receptor superfamily member 8
中文名称：肿瘤坏死因子受体超家族成员8
靶点别称：CD30，CD30L receptor，TNFRSF8，Lymphocyte activation antigen CD30，TNF Receptor Superfamily Member 8，D1S166E，Tumor Necrosis Factor Receptor Superfamily， Member 8，Cytokine Receptor CD30，CD30 Antigen，Ki-1，Ki-1 Antigen，Tumor Necrosis Factor Receptor Superfamily Member 8

上市药物数量：1
临床药物数量：14
最高研发阶段：批准上市

CD30产品列表

筛选结果

产品库

在线 (10)

物种

标签

属性

标记

货号	物种	产品描述
CD0-H5250	Human	Human CD30 / TNFRSF8 Protein, Fc Tag (MALS verified)
CD0-H82E6	Human	Biotinylated Human CD30 / TNFRSF8 Protein, Avitag™,His Tag (MALS verified)
TN8-H5250	Human	Human CD30 / TNFRSF8 Protein, Llama IgG2b Fc Tag, low endotoxin
CD0-HF250	Human	FITC-Labeled Human CD30 / TNFRSF8 Protein, Fc Tag
CD0-H52H5	Human	Human CD30 / TNFRSF8 Protein, His Tag
CD0-C52H4	Canine	Canine CD30 / TNFRSF8 Protein, His Tag
CD0-HP2E3	Human	PE-Labeled Human CD30 / TNFRSF8 Protein, His Tag (Site-specific conjugation)
CD0-HF2H4	Human	FITC-Labeled Human CD30 / TNFRSF8 Protein, His Tag
CD0-H82F4	Human	Biotinylated Human CD30 / TNFRS8 Protein, Fc,Avitag™ (MALS verified)
EP-135	Human	CD30 [Biotinylated] : CD30L Inhibitor Screening ELISA Kit

CD0-H5250|Human CD30 / TNFRSF8 Protein, Fc Tag (MALS verified)

182XXXXXXX2

3人赞

CD30的产品有很多，各种标签的，我选择的hFc标签的蛋白，同时购买了CD30L,做了Fortebio实验，结果还不错。
>
2019-10-10

CD0-HF2H4|FITC-Labeled Human CD30 / TNFRSF8 Protein, His Tag

932XXXXXXX

3人赞

Our research group work with CAR-T therapy for the treatment of hematological malignancies, and use the Fitc-Labeled Human CD30 protein for detection of CAR30 cells in patients by flow cytometry. Our results are fantastic, because the observe consistency and a reproducible experiments by flow cytometry. The logistic speed is very effective and allows us to work always up to date with our projects.
2021-10-11

CD0-HF2H4|FITC-Labeled Human CD30 / TNFRSF8 Protein, His Tag

139XXXXXXX2

2人赞

我们购买的这个荧光标记蛋白，染色效果很好，结果稳定可靠，在以后的试验中，我会再次选择这Acro公司的蛋白和抗体。期待得到更好的结果。
2021-07-22

查看更多评论

CD30 分子别名

TNFRSF8,CD30,D1S166E,Ki-1

CD30 分子背景

Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

CD30 前沿进展

CD30上市药物信息

英文名称	中文名称	研发代码	研发阶段	公司	最早商品名	最早批准国家	最早适应症	最早批准公司	最早批准日期	适应症	临床试验
Brentuximab vedotin	维布妥昔单抗	cAC10-vcMMAE; cAC10-Val-Cit-MMAE; SGN-30; SGN-35; cAC-10; SGD-1010	批准上市	Millennium Pharmaceuticals Inc, Seattle Genetics Inc	安适利, Adcetris	Mainland China	蕈样真菌病, 原发性皮肤间变性大细胞淋巴瘤	Bsp Pharmaceuticals Spa	2011-08-19	系统性红斑狼疮, 生殖细胞和胚胎肿瘤, 卡波济氏肉瘤, 淋巴瘤样丘疹病, 蕈样真菌病, 弥漫性硬皮病, T-细胞淋巴瘤, 非霍奇金淋巴瘤, 皮肤T细胞淋巴瘤, 淋巴瘤, 急性髓细胞样白血病, 间变大细胞淋巴瘤, Sezary综合征, 原发性皮肤间变性大细胞淋巴瘤, B-细胞淋巴瘤, 急性淋巴细胞白血病, 肥大细胞白血病, 肠病相关的T细胞淋巴瘤, 系统性硬皮病, 骨髓增生异常综合征, 系统性肥大细胞增多症, 移植物抗宿主病, 霍奇金病, 难治性贫血伴原始细胞过多, HIV感染, 血液疾病, 实体瘤, 周围T-细胞淋巴瘤	详情

CD30临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
Anti-CD30 CAR-T cell therapy (National Cancer Institute)	Hu30-CD28z	临床一期	美国国立癌症研究所	淋巴瘤	详情
CD30.CAR	H-27721; CD30.CAR	临床一期	贝勒医学院	霍奇金病, 非霍奇金淋巴瘤	详情
Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine)	CAR30-NKT; CBM-C30.1; CD30ScFv-CD8-CD137-CD3zeta	临床二期	中国人民解放军总医院	霍奇金病	详情
EBV-specific-CAR.CD30	EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs	临床一期	贝勒医学院, 德克萨斯儿童医院, 卫理公会医院	霍奇金病, 非霍奇金淋巴瘤	详情
ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center)		临床二期	Unc Lineberger Comprehensive Cancer Center	X-连锁淋巴增生症, 淋巴瘤, 非霍奇金淋巴瘤	详情
HSP-CAR-30	HSP-CAR-30	临床二期	Fundació Institut De Recerca De L	霍奇金病, T-细胞淋巴瘤	详情
SGN-CD30C	SGN-CD30C	临床一期	Seattle Genetics	淋巴瘤	详情
CD30.CAR-EBVST cell therapy (Baylor College of Medicine)	TT-11X	临床一期	贝勒医学院, Tessa Therapeutics	弥漫性大B-细胞淋巴瘤	详情
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30，Shanghai Unicar-Therapy Bio-medicine)			上海优卡迪生物医药科技有限公司		详情
Anti CD30 CAR T Cell Therapy (First Song Therapeutics)			浙江大学		详情
MDX-1401	MDX-1401		Medarex		详情
Itezocabtagene autoleucel	TT-11		Tessa Therapeutics		详情
Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid)		临床一期	武汉波睿达生物科技有限公司	血液肿瘤, 霍奇金病, 间变大细胞淋巴瘤	详情
XmAb-2513	XmAb-2513		Xencor		详情
Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell)			Immune Cell		详情
AFM-13	AFM-13	临床二期	德州大学安德森癌症中心	周围T-细胞淋巴瘤, 霍奇金病, 蕈样真菌病	详情
Recombinant chimeric anti-CD30 monoclonal antibody-MCC-DM1	F0002-ADC; B-006	临床一期	上海交联药物研发有限公司, 上海复旦张江生物医药股份有限公司	周围T-细胞淋巴瘤, 血液肿瘤	详情

会议日历

会议一览

CD30